Financials Anhui Anke Biotechnology (Group) Co., Ltd.

Equities

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
10.22 ^CNY	+2.51%		+2.92%	-.--%

Apr. 25	Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 28	Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	15,849	20,044	21,448	15,623	17,094	17,094	-	-
Enterprise Value (EV) ¹	15,849	20,044	21,448	15,623	17,094	17,824	17,094	17,094
P/E ratio	126 x	56.5 x	101 x	21.8 x	20 x	17.3 x	14.6 x	-
Yield	0.99%	1.36%	-	-	-	-	-	-
Capitalization / Revenue	9.25 x	11.8 x	-	6.7 x	5.97 x	4.69 x	4.03 x	-
EV / Revenue	9.25 x	11.8 x	-	6.7 x	5.97 x	4.89 x	4.03 x	-
EV / EBITDA	68.4 x	40.5 x	-	16.9 x	16.8 x	13.9 x	11.4 x	-
EV / FCF	141 x	-	-	68.5 x	22.6 x	14.9 x	14.5 x	9.47 x
FCF Yield	0.71%	-	-	1.46%	4.43%	6.73%	6.9%	10.6%
Price to Book	6.03 x	7.07 x	-	-	-	-	-	-
Nbr of stocks (in thousands)	1,638,499	1,638,466	1,638,466	1,669,071	1,672,639	1,672,639	-	-
Reference price ²	9.673	12.23	13.09	9.360	10.22	10.22	10.22	10.22
Announcement Date	2/28/20	4/7/21	3/30/22	3/27/23	3/27/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,713	1,701	-	2,331	2,866	3,645	4,237	-
EBITDA ¹	231.7	494.3	-	924.8	1,020	1,283	1,501	-
EBIT ¹	165.2	424	-	842	924	1,170	1,380	1,658
Operating Margin	9.64%	24.92%	-	36.12%	32.24%	32.1%	32.57%	-
Earnings before Tax (EBT) ¹	163.4	416.1	-	833.8	919.9	1,174	1,392	1,683
Net income ¹	124.5	359	206.6	703.3	847.2	990	1,174	-
Net margin	7.27%	21.1%	-	30.17%	29.56%	27.16%	27.71%	-
EPS ²	0.0769	0.2167	0.1300	0.4300	0.5100	0.5900	0.7000	-
Free Cash Flow ¹	112.4	-	-	228.2	757.9	1,200	1,180	1,806
FCF margin	6.56%	-	-	9.79%	26.45%	32.92%	27.85%	-
FCF Conversion (EBITDA)	48.52%	-	-	24.68%	74.33%	93.53%	78.61%	-
FCF Conversion (Net income)	90.3%	-	-	32.45%	89.45%	121.21%	100.51%	-
Dividend per Share	0.0962	0.1667	-	-	-	-	-	-
Announcement Date	2/28/20	4/7/21	3/30/22	3/27/23	3/27/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	730	-	-
Net Cash position ¹	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	0.569 x	-	-
Free Cash Flow ¹	112	-	-	228	758	1,200	1,180	1,806
ROE (net income / shareholders' equity)	5.2%	13.3%	-	23.8%	24.9%	37%	56.2%	-
ROA (Net income/ Total Assets)	4.33%	10.7%	-	16.5%	-	26.8%	35.6%	-
Assets ¹	2,876	3,365	-	4,255	-	3,694	3,298	-
Book Value Per Share	1.600	1.730	-	-	-	-	-	-
Cash Flow per Share	0.1800	0.2800	-	-	-	-	-	-
Capex ¹	183	138	-	471	195	166	444	120
Capex / Sales	10.7%	8.12%	-	20.2%	6.81%	4.55%	10.48%	-
Announcement Date	2/28/20	4/7/21	3/30/22	3/27/23	3/27/24	-	-	-

¹CNY in Million

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

D+

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.22 CNY

Average target price

19.54 CNY

Spread / Average Target

+91.19%

	1st Jan change	Capi.
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.	-.--%	2.36B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B
INNOVENT BIOLOGICS, INC.	-4.33%	8.5B